Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
SC
Scribe Therapeutics Inc SCTX
$17.36
▲ +4.08%
(+$0.68)
🎈 Low Float
Open
$16.47
Prev Close
$16.68
Day Range
$16.01 – $18.31
52W Range
$13.50 – $39.60
Market Cap
$315.78M
Beta
0.20
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| IPO Date | 2026-07-24 |
| Shares Out. | 18,930,000 |
| Website | scribetx.com ↗ |
| Phone | 19086427374 |
About Scribe Therapeutics Inc
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Scribe Therapeutics Inc is a publicly traded company under the ticker symbol SCTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-11-01)
📰 Latest News for SCTX
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
Scribe Therapeutics To Present Data In American Heart Association’s Scientific Sessions On Its Three Clinical Programs